August 2013

Mount Sinai, Exosome Diagnostics partner

Friday, August 30, 2013

The Icahn School of Medicine at Mount Sinai and Exosome Diagnostics are collaborating on the R&D of real-time nucleic acid-based body-fluid diagnostics to advance personalized medicine. Exosome will provide technical and development support to Mount Sinai researchers along with early access to proprietary technology products upgrades. The five-year agreement will allow the companies to establish targeted research and biomarker discovery programs in oncology and inflammation. Exosome anticipates pursuing commercial development and FDA review of successful validations for in vitro diagnostics.

[Read More]

Meda acquires Acton Pharmaceuticals

Friday, August 30, 2013

Meda, an international specialty pharmaceutical company, has acquired Acton Pharmaceuticals for $135 million, plus a milestone payment of $10 million and royalties. The acquisition is expected to close during the fourth quarter and is subject to customary closing conditions and U.S. regulatory approval. Existing credit facilities will fund the acquisition.

[Read More]

Bosch Healthcare, Remedy Health Media partner to enhance patient engagement

Friday, August 30, 2013

Robert Bosch Healthcare Systems, a provider of telehealth systems, and Remedy Health Media, a provider of clinical resources and wellness tools, have partnered to develop and market a suite of web-based products and solutions focused on supporting better patient engagement in telehealth and compliance with medical care. The partnership combines Bosch’s evidence-based telehealth solutions for chronic medical and mental health conditions with Remedy’s design and development of patient engagement models to improve patients’ compliance with medical care and self-management skills.

[Read More]

ObsEva, Merck Serono ink license agreement

Friday, August 30, 2013

ObsEva, a Swiss-based, specialty biopharmaceutical company, signed a licensing agreement with Merck Serono, the biopharmaceutical division of Germany-based Merck, granting ObsEva worldwide development and commercialization rights to certain Merck Serono compounds for preterm labor. The details of the agreement were not disclosed. The funding will allow ObsEva to undertake the development of these compounds.

[Read More]

OPKO acquires Prolor Biotech

Friday, August 30, 2013

OPKO Health, a multinational biopharmaceutical and diagnostics company, has acquired Prolor Biotech, a clinical-stage biopharmaceutical company. Stockholders of Prolor will receive 0.9951 shares of OPKO common stock for each share of Prolor common stock. The stockholders of both companies approved all proposals presented at their respective stockholder meetings.

[Read More]